|
|
POLYDEX PHARMACEUTICALS PROVIDES THIRD QUARTER REPORT PLANT UPGRADES LAUNCH PRODUCTION INCREASES |
| |
|
|
|
|
POLYDEX ANNOUNCES COMMENCEMENT OF FOLLOW-UP STUDY OF USHERCELL |
| |
|
|
|
|
POLYDEX MOVING FORWARD WITH CONTRACEPTIVE DEVELOPMENT AND BUILDING FOR THE FUTURE |
| |
|
|
|
|
FINAL REPORT OF USHERCELL AS TREATMENT
FOR BACTERIAL VAGINOSIS RELEASED.
ADDITIONAL TRIALS REINFORCE SAFETY AND ACCEPTABILITY |
| |
|
|
|
|
POLYDEX REPORTS SECOND QUARTER
FINANCIAL RESULTS |
| |
|
|
|
|
ANALYSIS OF USHERCELL HIV TRIALS REVEALS DIFFERENCE IN SEROCONVERSION GROUPS NOT STATISTICALLY SIGNIFICANT POLYDEX CONTINUES CONTRACEPTIVE DEVELOPMENT |
| |
|
|
|
|
POLYDEX PHARMACEUTICALS LIMITED – 2007 FISCAL YEAR END RESULTS CONTINUED GROWTH OF CORE PRODUCT SALES A PRIORITY FOR FISCAL 2008 |
| |
|
|
|
|
POLYDEX PHARMACEUTICALS LIMITED – 2007 FISCAL YEAR END RESULTS CONTINUED GROWTH OF CORE PRODUCT SALES A PRIORITY FOR FISCAL 2008 |
| |
|
|
|
|
POLYDEX PHARMACEUTICALS ISSUES
INTERIM REPORT ON BUSINESS OPERATIONS |
| |
|
|
|
|
POLYDEX PHARMACEUTICALS REPORTS PHASE III TRIAL OF USHERCELL FOR HIV PREVENTION HALTED |
| |
|
|
| |
|
|
